Related Experiment Videos
The rationale behind intraperitoneal chemotherapy in gastrointestinal malignancies
Seminars in Oncology
|September 1, 1985
Summary
Intraperitoneal chemotherapy may improve tumor kill by delivering high drug concentrations directly to the liver and peritoneal surfaces. Further clinical trials are needed to confirm the effectiveness of this gastrointestinal cancer treatment.
Area of Science:
- Oncology
- Gastroenterology
- Pharmacology
Background:
- Local regional chemotherapy effectiveness is under investigation.
- Intraperitoneal (IP) chemotherapy is being studied for gastrointestinal (GI) malignancies.
- Drug delivery route and metabolism are critical factors in chemotherapy success.
Purpose of the Study:
- To assess the potential of IP chemotherapy for GI tumors.
- To evaluate if IP administration can achieve high drug concentrations in the liver and peritoneal space.
- To determine if IP chemotherapy improves tumor kill rates.
Main Methods:
- A study involving 5-fluorouracil (5-FU) in patients with metastatic colorectal carcinoma.
- Administration of chemotherapy via the intraperitoneal route.
- Measurement of portal drug concentrations.
Main Results:
- High portal drug concentrations of 5-FU were achieved using IP administration.
- IP therapy demonstrated potential for delivering high drug concentrations to the hepatic parenchyma and intraperitoneal space.
- The study suggests IP administration is a viable method for delivering chemotherapy.
Conclusions:
- Intraperitoneal chemotherapy shows promise for treating GI malignancies by enhancing drug delivery.
- Further clinical trials are necessary to establish the definitive efficacy of IP chemotherapy.
- High drug concentrations in the liver and peritoneal cavity may lead to improved tumor response.